These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 16625863)

  • 21. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M; Strosberg J
    Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in the systemic treatment of pancreatic neuroendocrine tumors.
    Yalcin S
    Cancer Treat Rev; 2011 Apr; 37(2):127-32. PubMed ID: 20705397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
    Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
    J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
    Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
    Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].
    Uomo G; Germano D; Rabitti PG
    Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspectives of new potential therapeutic applications of somatostatin analogs.
    Pawlikowski M; Melen-Mucha G
    Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Delaunoit T; Rubin J; Neczyporenko F; Erlichman C; Hobday TJ
    Mayo Clin Proc; 2005 Apr; 80(4):502-6. PubMed ID: 15819288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 32. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Modlin I
    Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
    Kvols LK; Woltering EA
    Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Chandrasekharan C
    Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
    Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
    United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
    Hasskarl J; Kaufmann M; Schmid HA
    Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
    Boucher JE; Sommers R
    Clin J Oncol Nurs; 2018 Oct; 22(5):565-568. PubMed ID: 30239510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotherapies for GEP-NETs.
    Öberg K
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):833-41. PubMed ID: 23582922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
    Cuccurullo V; Di Stasio GD; Mansi L
    Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiology of somatostatin receptors.
    Guillermet-Guibert J; Lahlou H; Cordelier P; Bousquet C; Pyronnet S; Susini C
    J Endocrinol Invest; 2005; 28(11 Suppl International):5-9. PubMed ID: 16625838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.